Autonomix Medical, Inc. Announces Successful Initial Trial Phase and Plans for Market Expansion Study in Pancreatic Cancer Pain Management

Dr. Schwartz outlines Autonomix's trial results and plans for further studies on pain relief in pancreatic cancer.

Quiver AI Summary

Dr. Robert Schwartz, Chief Medical Officer of Autonomix Medical, announced successful results from the initial trial phase of their proof-of-concept study, POC 1, which demonstrated significant pain reduction in patients with pancreatic cancer. The company plans to expand its research with a new market expansion study, POC 2, targeting additional visceral cancers and earlier stages of pancreatic cancer, set to begin in the second quarter of 2025. Autonomix is focused on innovative technologies for diagnosing and treating nervous system diseases, using a novel catheter-based microchip sensing array to enhance neural signal detection and enable transvascular treatments. The company's technology is still investigational and not yet marketed in the U.S.

Potential Positives

Successful meeting of initial phase in the first-in-human proof-of-concept trial ("PoC 1") indicates progress and potential in pain management for pancreatic cancer.
Plans to initiate a follow-on phase ("PoC 2") for market expansion into additional visceral cancers and earlier stage pancreatic cancer, showing a commitment to broadening the scope of research and application.
The innovative technology features a catheter-based microchip sensing array with the potential for superior sensitivity in detecting neural signals, representing a significant advancement in the field.

Potential Negatives

The technology is still investigational and has not yet been cleared for marketing in the United States, indicating a lack of regulatory approval which could hinder market confidence.
Transitioning from proof-of-concept to a follow-on phase indicates that the product is in the early stages of development, which may be perceived as a higher risk for investors.
The focus on a specific and severe condition like pancreatic cancer, which has limited treatment options, may raise concerns about the market size and commercial viability of the company's offerings.

FAQ

What is the purpose of Autonomix's initial trial phase “POC 1”?

The purpose of “POC 1” was to demonstrate clinically meaningful pain reduction in patients with pancreatic cancer.

When will the next study, “POC 2”, begin?

The “POC 2” market expansion study is expected to begin in Q2 2025.

What innovative technology does Autonomix use?

Autonomix uses a catheter-based microchip sensing array to detect and differentiate neural signals with greater sensitivity.

What types of conditions can Autonomix's technology address?

The technology has potential applications in cardiology, hypertension, chronic pain management, and more across a wide disease spectrum.

Is Autonomix's technology currently approved for marketing?

No, Autonomix's technology is investigational and has not yet been cleared for marketing in the United States.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$AMIX Hedge Fund Activity

We have seen 0 institutional investors add shares of $AMIX stock to their portfolio, and 15 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

MARINER, LLC removed 5,619 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $21,127
GEODE CAPITAL MANAGEMENT, LLC removed 4,481 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $16,848
HRT FINANCIAL LP removed 3,053 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $11,479
PNC FINANCIAL SERVICES GROUP, INC. removed 1,837 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $6,907
CWM, LLC removed 1,000 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $3,760
VIRTU FINANCIAL LLC removed 756 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $2,842
TOWER RESEARCH CAPITAL LLC (TRC) removed 251 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $943

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Full Release

Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses key learnings from initial trial phase (“POC 1”) where clinically meaningful pain reduction was demonstrated

Outlines Company’s plans to initiate market expansion study (“POC 2”) into additional visceral cancers and earlier stage pancreatic cancer, expected to begin Q2 2025

Access the “What This Means” video here

THE WOODLANDS, TX, May 01, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it recently participated in a Virtual Investor “What This Means” segment .

For the segment, Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discussed the Company’s successfully met initial phase of the first-in-human proof-of-concept trial (“PoC 1”) and the advancement to a follow-on phase (“PoC 2”) evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with pancreatic cancer pain.

The “What This Means” video can be accessed here .

About Autonomix Medical, Inc.

Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.

We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.

For more information, visit autonomix.com and connect with the Company on X , LinkedIn , Instagram and Facebook .

Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
[email protected]